Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


Tolera Therapeutics gets $4M for organ transplant rejection drug

10:31 am by | 0 Comments

Cleveland Clinic spinoff Tolera Therapeutics Inc. has raised more than $4 million in equity to continue developing a drug that fights organ rejection in transplant patients, according to a regulatory filing with the Securities and Exchange Commission.

The Series B funding will go toward a Phase 2 clinical trial of Tolera’s lead drug candidate, TOL101, said James Herrmann, the company’s chief operating officer and co-founder.

The drug is designed to suppress the immune systems of patients who have received organ transplants, which can fail because the body rejects and attacks the transplanted organ. Tolera has begun the trial and expects to complete it in a year, Herrmann said.

Tolera also plans to clinically investigate the drug’s ability to fight other autoimmune disorders, such as Type 1 diabetes and multiple sclerosis, Herrmann said. Those trials could start in about a year.

Advertisement

The company may raise another $2 million for the round, bringing the total to $6 million, if it can find new investors. So far, the latest round includes contributions from Tolera’s existing investors, Herrmann said.

In 2008, Tolera raised an $8 million Series A round. Triathlon Medical Ventures in Cincinnati led the round, which included contributions from the Southwest Michigan First Life Science Fund in Kalamazoo and Hopen Therapeutics Inc. in Grand Rapids, Mich.

The company has raised $14 million since its inception, Herrmann said.

Tolera was chosen as one of this year’s (pdf) “Michigan 50 Companies to Watch” in April by local economic development groups.

Cleveland Clinic Innovations spun off Tolera in 2007. The company moved to Kalamazoo in mid-2008 to take advantage of the area’s drug development resources and to be closer to investors, Herrmann said.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Brandon Glenn

By Brandon Glenn MedCity News

Brandon Glenn is the Ohio bureau chief for MedCity News.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement